

# Stock Sentiment Analysis Report

Pacific Biosciences (PACB)

Analysis Period: 2026-03-24 to 2026-04-23 (30 days)

Generated: 2026-04-23 10:08:34

## Executive Summary


Sentiment analysis for Pacific Biosciences (PACB) from 2026-03-24 to 2026-04-23. Analyzed 71 items across FDA and news sources.

## Sentiment Breakdown

Category	Count	Percentage
Positive	20	28.2%
Negative	12	16.9%
Neutral	39	54.9%
<b>Total</b>	<b>71</b>	<b>100.0%</b>

**Overall Sentiment: NEUTRAL**

## Sentiment Trend Over Time



## Key Findings

No key findings available.

## Top Positive Events

Title	Source	Date	Score
Single Cell Sequencing Market Outlook Report 2026-...	news	2026-04-20	0.941
Oncology Precision Medicine Market Trends and Inve...	news	2026-03-27	0.637
Reduced legacy precipitation decreases microbial c...	pubmed	2026 Apr 1	0.625
Pacific Biosciences stock (US6932471010): Is long-...	alpha_vantage	2026-04-18	0.511
Scaling genomic reanalysis to unlock diagnoses and...	pubmed	2026 Apr 9	0.494

## Top Negative Events

Title	Source	Date	Score
Genomic analysis of human-infecting <i>Leptospira bor...</i>	news	2026-03-27	-0.791
Pacific Biosciences of California unveils SPRQ-Nx ...	alpha_vantage	2026-04-09	-0.660
Powering cancer testing research with HiFi whole g...	alpha_vantage	2026-04-02	-0.660
Pacific Biosciences of California (PACB) Suffers a...	alpha_vantage	2026-04-14	-0.637
From genome to therapy: How HiFi long-read sequenc...	alpha_vantage	2026-04-17	-0.494